Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(16 sites)
China
The First Affiliated Hospital of USTC, Hefei, Anhui The Second Hospital of Anhui Medical University, Hefei, Anhui Guangdong Provincial People's Hospital, Guangzhou, Guangdong Southern Medical University Nanfang Hospital, Guangzhou, Guangdong Shenzhen People's Hospital, Shenzhen, Guangdong The Affiliated Hospital of Guilin Medical University, Guilin, Guangxi The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Affiliated Hospital of Hebei University, Baoding, Hebei Tangshan Central Hospital, Tangshan, Hebei Henan Cancer Hospital, Zhengzhou, Henan Zhongda Hospital Southeast University, Nanjing, Jiangsu The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi The First Hospital of China Medical University, Shenyang, Liaoning The First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an, Shaanxi Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin Municipality